Loss and reduced expression of PTEN correlate with advanced‑stage gastric carcinoma

Zhu,Xuehua; Qin,Xia; Fei,Maogui; Hou,Wenmin; Greshock,Joel; Bachman,Kurtis  E.; Kang,Jiuhong; Qin,Crystal  Ying

doi:10.3892/etm.2012.749

Loss and reduced expression of PTEN correlate with advanced‑stage gastric carcinoma

Authors:
- Xuehua Zhu
- Xia Qin
- Maogui Fei
- Wenmin Hou
- Joel Greshock
- Kurtis E. Bachman
- Jiuhong Kang
- Crystal Ying Qin
View Affiliations

Affiliations: Shanghai Key Laboratory of Signaling and Disease Research, School of Life Science and Technology, Tongji University, Shanghai, P.R. China, Department of Oncology, GlaxoSmithKline Research and Development Center, Shanghai, P.R. China , Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences (CAS), Shanghai, P.R. China, Cancer Research, GlaxoSmithKline, Collegeville, PA, USA
Published online on: October 15, 2012 https://doi.org/10.3892/etm.2012.749
Pages: 57-64

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phosphatase and tensin homolog (PTEN) is a tumor suppressor involved in multiple cell processes. To investigate the role of PTEN in the development of gastric carcinoma, we determined the expression pattern of PTEN in primary gastric carcinoma and in paired adjacent non‑neoplastic tissue. We also determined the correlation of PTEN expression with clinicopathological characteristics and patient survival. Overall, 159 gastric carcinomas and 151 paired adjacent non‑neoplastic tissues were used in the present study. PTEN expression was determined using tissue microarrays and immunohistochemistry. The clinical sensitivity and specificity of PTEN expression were calculated using receiver operator characteristic curves. Results showed that the loss of cytoplasmic PTEN was significantly more frequent in carcinoma tissue compared with adjacent non‑neoplastic tissue (62 vs. 5%, respectively; P<0.0001). PTEN expression was markedly downregulated in carcinoma tissues compared with adjacent non‑neoplastic tissues. The loss of cytoplasmic PTEN expression was positively correlated with histological stage (P=0.016). The loss of nuclear or total PTEN, and downregulation of total PTEN expression, was significantly different between American Joint Committee on Cancer tumors of stage I and stages II-IV. A low cytoplasmic or total PTEN expression showed high clinical sensitivity and specificity for gastric carcinoma. However, PTEN expression was not significantly associated with overall or 3‑year survival rates. The findings of the present study indicated that PTEN expression may be a molecular diagnostic marker for gastric cancer. Thus, the loss or reduced expression of PTEN potentially correlate with advanced stages of gastric carcinoma.

View Figures

View References

1	Roder DM: The epidemiology of gastric cancer. Gastric Cancer. 5:5–11. 2002. View Article : Google Scholar
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
3	Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
4	Li DM and Sun H: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57:2124–2129. 1997.PubMed/NCBI
5	Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
6	Maehama T and Dixon JE: The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
7	Goberdhan DC and Wilson C: PTEN: tumour suppressor, multifunctional growth regulator and more. Hum Mol Genet. 12:R239–R248. 2003. View Article : Google Scholar : PubMed/NCBI
8	Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:29–39. 1998. View Article : Google Scholar : PubMed/NCBI
9	Besson A, Robbins SM and Yong VW: PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem. 263:605–611. 1999. View Article : Google Scholar : PubMed/NCBI
10	Waite KA and Eng C: Protean PTEN: form and function. Am J Hum Genet. 70:829–844. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kang YH, Lee HS and Kim WH: Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 82:285–291. 2002. View Article : Google Scholar : PubMed/NCBI
12	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German).
13	Bignell GR, Greenman CD, Davies H, et al: Signatures of mutation and selection in the cancer genome. Nature. 463:893–898. 2010. View Article : Google Scholar : PubMed/NCBI
14	Salmena L, Carracedo A and Pandolfi PP: Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008. View Article : Google Scholar : PubMed/NCBI
15	Carracedo A, Alimonti A and Pandolfi PP: PTEN level in tumor suppression: how much is too little? Cancer Res. 71:629–633. 2011. View Article : Google Scholar : PubMed/NCBI
16	Hollander MC, Blumenthal GM and Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
17	Backman SA, Ghazarian D, So K, et al: Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci USA. 101:1725–1730. 2004. View Article : Google Scholar : PubMed/NCBI
18	Lee JI, Soria JC, Hassan KA, et al: Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg. 127:1441–1445. 2001. View Article : Google Scholar : PubMed/NCBI
19	Tachibana M, Shibakita M, Ohno S, et al: Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer. 94:1955–1960. 2002. View Article : Google Scholar : PubMed/NCBI
20	McMenamin ME, Soung P, Perera S, Kaplan I, Loda M and Sellers WR: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59:4291–4296. 1999.PubMed/NCBI
21	Depowski PL, Rosenthal SI and Ross JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol. 14:672–676. 2001. View Article : Google Scholar : PubMed/NCBI
22	Sano T, Lin H, Chen X, et al: Differential expression of MMAC/ PTEN in glioblastoma multiforme: relationship to locali zation and prognosis. Cancer Res. 59:1820–1824. 1999.PubMed/NCBI
23	Zheng H, Takahashi H, Murai Y, et al: Low expression of FHIT and PTEN correlates with malignancy of gastric carcinomas: tissue-array findings. Appl Immunohistochem Mol Morphol. 15:432–440. 2007. View Article : Google Scholar : PubMed/NCBI
24	Leslie NR and Foti M: Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci. 32:131–140. 2011. View Article : Google Scholar : PubMed/NCBI
25	Harima Y, Sawada S, Nagata K, Sougawa M, Ostapenko V and Ohnishi T: Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. Int J Oncol. 18:493–497. 2001.PubMed/NCBI
26	Yoshimoto M, Cunha IW, Coudry RA, et al: FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 97:678–685. 2007. View Article : Google Scholar : PubMed/NCBI
27	Deng H, Wu RL, Zhou HY, Huang X, Chen Y and Liu LJ: Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer. World J Gastroenterol. 12:1013–1017. 2006.PubMed/NCBI
28	Bai Z, Ye Y, Chen D, et al: Homeoprotein Cdx2 and nuclear PTEN expression profiles are related to gastric cancer prognosis. APMIS. 115:1383–1390. 2007. View Article : Google Scholar : PubMed/NCBI